PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 187 filers reported holding PDL BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is 2.92 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,050,000 | -57.8% | 334,538 | -50.0% | 0.06% | -58.8% |
| Q1 2019 | $2,488,000 | +11.2% | 669,076 | -13.3% | 0.14% | +7.1% |
| Q4 2018 | $2,238,000 | +80.5% | 771,644 | +63.6% | 0.13% | +115.3% |
| Q3 2018 | $1,240,000 | +111.6% | 471,644 | +88.7% | 0.06% | +43.9% |
| Q2 2018 | $586,000 | -20.4% | 250,000 | 0.0% | 0.04% | -18.0% |
| Q1 2018 | $736,000 | +7.3% | 250,000 | 0.0% | 0.05% | +8.7% |
| Q4 2017 | $686,000 | -27.8% | 250,000 | -10.7% | 0.05% | +1433.3% |
| Q3 2017 | $950,000 | +666.1% | 280,000 | +460.0% | 0.00% | – |
| Q2 2017 | $124,000 | +8.8% | 50,000 | 0.0% | 0.00% | – |
| Q1 2017 | $114,000 | +44.3% | 50,000 | +34.9% | 0.00% | – |
| Q4 2016 | $79,000 | -98.4% | 37,058 | -94.0% | 0.00% | -100.0% |
| Q3 2013 | $4,923,000 | – | 617,659 | -31.2% | 0.02% | – |
| Q2 2013 | $0 | – | 897,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |